REVLIMID is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

Recommended dose adjustments1

Recommended starting dose adjustments for patients with renal impairment.

REVLIMID® Dose Modifications Based on Renal Function

Capsules shown are not actual size.

Dose modification is recommended to manage Grade 3 or 4 hematologic events thought to be related to therapy with REVLIMID.1


REVLIMID® Dose Modifications Based on Platelet Levels


REVLIMID® Dose Modifications Based on Neutrophil Levels

For non-hematologic Grade 3 or 4 toxicities judged to be related to REVLIMID, hold treatment and restart treatment at the next lower dose level when toxicity has resolved to ≤Grade 2 at the physician’s discretion.

Permanently discontinue REVLIMID for angioedema, anaphylaxis, Grade 4 rash, skin exfoliation, bullae, or any other severe dermatologic reactions.

REVLIMID® Dose Modifications Data

Get helpful resources for your practice and patients.

Access Now